<DOC>
	<DOCNO>NCT01785875</DOCNO>
	<brief_summary>This study design describe long-term safety efficacy etelcalcetide ( AMG 416 ) treatment SHPT adult CKD hemodialysis .</brief_summary>
	<brief_title>Extension Study Etelcalcetide Treatment Secondary Hyperparathyroidism ( SHPT ) Patients With Chronic Kidney Disease ( CKD ) Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Subject understands study procedure agree participate study give write informed consent . Subject must complete treatment followup period , discontinue rise intact parathyroid hormone ( iPTH ) , AMG 416 phase 3 parent study prior start dose study : 20120229 ( NCT01785849 ) , 20120230 ( NCT01788046 ) , 20120359 ( NCT01932970 ) . Subject agree participate another study investigational agent study . Other Inclusion Criteria may apply Currently receive treatment another investigational device drug study . Currently receive investigational procedure participate study . Subject known sensitivity product component administer dose . Subject unstable medical condition base medical history , physical examination , routine laboratory test , otherwise unstable judgment Investigator . Other Exclusion Criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Secondary Hyperparathyroidism ( SHPT ) , chronic kidney disease ( CKD ) , hemodialysis , parathyroid hormone ( PTH ) , hypocalcemia , bone mineral metabolism</keyword>
</DOC>